58584-63-7

Basic information

• Product Name: (6-methoxypyridin-3-yl)methanol
• Synonyms: (6-methoxypyridin-3-yl)methanol;2-Methoxypyridine-5-metha...;2-Methoxypyridine-5-Methanol;6-Methoxy-3-PyridineMethanol;2-Methoxy-5-hydroxymethylpyridine;2-Methoxy-5-pyridinemethanol;5-(Hydroxymethyl)-2-methoxypyridine;6-Methoxy-3-(hydroxymethyl)pyridine
• CAS NO: 58584-63-7
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.16
• Mol File: 58584-63-7.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 258℃
• Flash Point: 110℃
• Appearance: /
• Density: 1.155
• Vapor Pressure: 0.00729mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.42±0.10(Predicted)
• CAS DataBase Reference: (6-methoxypyridin-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (6-methoxypyridin-3-yl)methanol(58584-63-7)
• EPA Substance Registry System: (6-methoxypyridin-3-yl)methanol(58584-63-7)

Safety Data

• Hazardous Substances Data: 58584-63-7(Hazardous Substances Data)

Usage

General Description

(6-methoxypyridin-3-yl)methanol is a chemical compound with the molecular formula C7H9NO2. It is a derivative of pyridine, a six-membered ring structure with five carbon atoms and one nitrogen atom. The presence of a methoxy group and a hydroxyl group in the compound suggests potential applications as a building block in organic synthesis. This chemical may be used in pharmaceutical research, as well as in the development of new materials and compounds. Its specific properties and potential uses would depend on further research and testing.

InChI:InChI=1/C7H9NO2/c1-10-7-3-2-6(5-9)4-8-7/h2-4,9H,5H2,1H3

Upstream product

• 50-00-0 formaldehyd 
• 163105-89-3 2-methoxy-pyridine-5-boronic acid 
• 144-55-8 sodium hydrogencarbonate 
• 3099-50-1 3-trichloromethyl-pyridine 
• 7440-05-3 palladium 
• 65873-72-5 6-methoxy-3-pyridinecarboxaldehyde 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 26218-80-4 6-methoxy-nicotinic acid methyl ester 
• 66572-55-2 6-methoxynicotinic acid 

Downstream Products

• 1191905-07-3 methyl 1-((6-methoxypyridin-3-yl)methyl)-1H-indole-6-carboxylate 
• 201294-65-7 1-benzyl-5-(hydroxymethyl)pyridin-2(1H)-one 
• 1227725-17-8 (±)-1-((1-benzyl-6-oxopiperidin-3-yl)methyl)pyridin-2(1H)-one 
• 744212-68-8 (±)-1-benzyl-5-(hydroxymethyl)piperidin-2-one 
• 1606974-75-7 2-(6-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)oxy)pyridin-3-yl)acetamide 
• 1606977-19-8 2-(6-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)oxy)pyridin-3-yl)acetonitrile 
• 1009602-42-9 7-methoxy-2-(methoxymethyl)pyrazolo[1,5-a]pyridine-4-carboxylic acid 
• 1009602-43-0 7-Methoxy-2-methoxymethylpyrazolo[1,5-a]pyridine-4-carboxylic acid 4-nitrophenyl ester 
• 1009603-03-5 C₁₆H₁₀F₃N₃O₅ 

Relevant articles and documents

RET inhibitor, pharmaceutical composition and application thereof

The invention belongs to the field of medicines, and relates to an RET inhibitor, a pharmaceutical composition and application thereof, specifically to a compound as shown in a formula (I), or a stereoisomer, a geometrical isomer, a tautomer, nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I). The invention also relates to a pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition thereof in manufacture of medicine, wherein the medicine is particularly used for treatment and prevention of diseases and disorders associated with available RET, including cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).